Patient Care Editorial Staff

Primary care clinicians are on the frontline of detecting early cognitive decline. Help us understand your challenges by taking this short survey.

Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.

Data on zabalafin hydrogel topical therapy may offer a single, comprehensive approach to manage AD across multiple disease stages.

Data from the TRuE-PN trial program were presented at the 2025 American Academy of Dermatology Annual Meeting in Orlando, offering important insights into potential new therapeutic options for this debilitating condition.

Icotrokinra is the first targeted oral peptide designed to selectively block the IL-23 receptor, which is implicated in multiple inflammatory conditions including plaque psoriasis.

Two posters at AAD 2025 highlighted different challenges of managing patients with HS.

The findings highlight the potential of the interleukin-23 inhibitor to address a notoriously difficult-to-treat manifestation of psoriasis.

The findings from the long-term extension ADjoin study will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting.

Preview the posters and abstracts covering atopic dermatitis advances from Arcutis, Incyte, Lilly and Sanofi/Regeneron.

The FDA set the Prescription Drug User Fee Act (PDUFA) date for December 16, 2025.

Investigators concluded that dupilumab reduced exacerbation rates, improved lung function, and decreased systemic corticosteroid use in patients with COPD driven by type 2 inflammation.

The FDA approval of neffy 1 mg follows the earlier approval of the 5 mg version in August 2024.

The 2025 measles outbreak in Texas has reignited discussion surrounding vaccine-preventable diseases and the importance of maintaining high immunization rates.

Data on the epinephrine nasal spray will include findings from an efficacy study comparing anaphylaxis symptoms during oral food challenge, according to ARS.

Investigators reported that roflumilast cream 0.05% significantly reduced AD severity as early as Week 1, with a notable effect on pruritus seen in as little as 24 hours.

The Metrix COVID/Flu molecular test detects and differentiates SARS-CoV-2, influenza A, and influenza B in approximately 20 minutes.

These label changes to Sublocade from Indivior mark a significant advancement in the management of moderate to severe opioid use disorder.

The clearance enables Alphyn to initiate global phase 2b clinical trials, which are anticipated to begin in the first quarter of 2025.

Merilog joins two long-acting insulin biosimilar products approved in 2021, bringing the total to three insulin biosimilars available in the United States.

The development comes at a time when cannabis use disorder has risen steadily in the United States.

The Winter Clinical Hawaii Dermatology Conference will kick off on the Big Island on February 14th. Check out the agenda and the option to attend virtually.

The FDA set a PDUFA action date of December 12, 2025 for lerodalcibep, according to LIB Therapeutics.

The FDA has set the Prescription Drug User Fee Act target action date for bronchiectasis for August 12, 2025, Insmed Incorporated announced.

Vesper Bio anticipates completing enrollment and dosing by mid-2025 in the Phase 1B/2A trial for VES001.

These test panels allow clinicians to diagnose multiple STIs from a single specimen, with results available in about 20 minutes.

Cebranopadol, an investigational oral dual-NMR agonist, satisfied the primary endpoint of statistically significant reduction in pain intensity compared to placebo following abdominoplasty surgery.

The approval of esketamine follows an FDA Priority Review and is based on data showing that esketamine alone demonstrated rapid and superior improvement in depressive symptoms compared with placebo.

Findings of the study support the AHS 2024 statement supporting CGRP inhibitors as first-line options and calling for reducing overall costs of migraine treatment.

An earlier phase 2 study found statistically significant improvement of MDD in female participants.

The adcomm meeting is expected to happen in the first half of 2025, and means the FDA expects to miss the target PDUFA date.